Lipeng Guo

Lipeng Guo


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
RLRuiyuan Li
Ruiyuan Li
AAAili Atawula
Aili Atawula
HLHaonan Li
Haonan Li
MLMoran Li
Moran Li
JTJiamin Tang
Jiamin Tang
LGLipeng Guo
Lipeng Guo
This study aims to investigate novel inflammatory markers, including the systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and aggregate inflammatory score index (AISI), and their relationship with coronary heart disease (CHD) in patients with hypertension (HT) using data from the National Health and Nutrition Examination Survey (NHANES). We conducted a cross-sectional study using complete data from the 2005–2016 NHANES survey. A total of 9,242 hypertensive participants aged 18 years or older were included in the study. Participants were divided into HT group and HT combined with CHD group. SII was calculated as PC × NC/LC, SIRI was calculated as NC × MC/LC, and AISI was calculated as MC × PC × NC/LC. Additionally, demographic, lifestyle factors and health-related information was gathered. Logistic regression models were utilized to pinpoint SII, SIRI, and AISI associated with HT combined with CHD, and constructed three nomogram models to forecast HT combined with CHD risk. In our cohort of 9,242 patients, 2,055 (30.77%) had CHD. Higher levels of log2-SII (OR 1.10, 95%CI: 1.03–1.17, P = 0.003), log2-SIRI (OR 1.27, 95%CI: 1.19–1.35, P < 0.001) and log2-AISI (OR 1.13, 95%CI: 1.07–1.19, P < 0.001) were associated with an increased likelihood of CHD in hypertensive patients. Elevated log2-SII, log2-SIRI, and log2-AISI, along with male gender, older age, non-Mexican American ethnicity, family poverty income ratio (PIR) < 1.5, and smoking, were identified as risk factors for CHD in hypertensive populations. Calibration curves were constructed to assess the deviation between predicted and actual values, with 1,000 bootstrap iterations showing good consistency between predictions and observed outcomes. AUC values of the three models were 0.724 (95% CI: 0.712–0.736), 0.730 (95% CI: 0.718–0.741), and 0.726 (95% CI: 0.714–0.737), respectively. All the three models had good discrimination power. Decision curve analysis indicated that all three nomogram models are effective in clinical practice. These novel immune-inflammatory markers (SII, AISI, SIRI) offer a simple, non-invasive, and cost-effective screening tool with promising clinical application for predicting CHD risk in HT population. They have the potential to guide personalized treatment, aligning with the goals of precision medicine.

1 January 2025 in Open Medicine
Verified
Journal Article
Open access
PDF file
RLRuiyuan Li
Ruiyuan Li
LGLipeng Guo
Lipeng Guo
BLBin Liang
Bin Liang
WSWei Sun
Wei Sun
FHFeng Hai
Feng Hai
Background: The immune system is closely related to hypertension. Hypertension is an immune disorder to a certain extent, and inflammation is the basis of abnormally elevated blood pressure (BP). The accumulation of T cells and their cytokines can increase BP and end organ damage. T cells are activated by antigen-presenting cells of the innate immune system or by the influence of a high-sodium diet, the self-environment, or the gut microbiota. These cells produce inflammatory factors and cytokines, such as interleukin-17A (IL-17A) in T helper 17 cells, causing vascular inflammation, hypertension, and target organ damage Methods: In this article, we provide an insightful review of the research progress regarding the role of IL-17A in the pathogenesis of hypertension and its effects on different organs while emphasizing the role of IL-17A and its mediated functions in the kidneys, brain, intestines, and vascular system in the development and progression of hypertension. Results: At the organ level, IL-17A is involved in the development and progression of hypertension in the kidneys, brain, intestines, and blood vessels, interacting with multiple signal pathway. Conclusions: These findings have significant implications for developing future immunomodulatory therapies, which may lead to the development of potential treatments for hypertension.